Buparlisib, a pan‐PI3K inhibitor, has demonstrated desirable tolerability at a daily dosage of 100 mg when administered with cetuximab in recurrent/metastatic HNSCC, showing signs of disease stabilization even in patients previously treated with cetuximab. This evidence concerns the gene PIK3CG and head and neck squamous cell carcinoma.